What You Should Know:
– Abbott and Medtronic announced a groundbreaking partnership to develop an integrated continuous glucose monitoring (CGM) system designed to seamlessly work with Medtronic’s automated insulin delivery (AID) and smart insulin pen systems.
– The strategic collaboration aims to improve diabetes management by enabling more precise insulin dosing and reducing the burden on patients.
CGM System and Insulin Delivery Devices Integration
The new CGM sensor, developed by Abbott and based on its FreeStyle Libre technology, will be exclusively integrated with Medtronic’s AID algorithms. This integration will allow for automatic insulin adjustments, helping people with diabetes maintain better glucose control.
The partnership targets over 11 million people worldwide who rely on multiple daily insulin injections to manage their Type 1 or Type 2 diabetes. By combining Abbott’s leading CGM technology with Medtronic’s expertise in insulin delivery, the two companies aim to enhance the lives of millions of people living with diabetes.
While the financial terms of the partnership were not disclosed, it is expected to strengthen both companies’ positions in the diabetes care market.
“This partnership pairs two global leaders in glucose sensing technology and insulin delivery,” said Jared Watkin, executive vice president of Abbott’s diabetes care business. “Libre technology has set the standard for accurate, accessible, easy-to-use and reliable continuous glucose monitoring. Connecting this CGM built for Medtronic’s insulin delivery systems and algorithms makes it easier for people to spend less time thinking about their diabetes and more time living.”
